Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Vivo Diagnóstico is a large provider of diagnostic imaging services. It owns a network of clinics located in Andalusia, Madrid and Aragon and offers services throughout Spain, providing diagnostic imaging services in mobile units, outsourced diagnostic services for hospitals and teleradiology services.
For over 25 years, the private equity firm NEXXUS-IBERIA has partnered with entrepreneurs and management teams to consolidate and accelerate the growth of their businesses.
Oaklins’ team in Spain advised Vivo Diagnóstico on all aspects of the transaction, from the design to the execution, negotiation and closing of the deal.
Sprechen Sie mit dem Deal Team
Transaktionen
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Mehr erfahrenRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Mehr erfahrenDie Lindenhofgruppe veräussert ihre Mehrheitsbeteiligung an der LabPoint an Affidea Switzerland
Die LabPoint Medizinische Laboratorien AG wurde von Affidea Switzerland AG übernommen. Mit Affidea hat die Lindenhofgruppe AG einen starken strategischen Partner für die Weiterentwicklung der LabPoint gewonnen. Die Lindenhofgruppe bleibt bedeutende Aktionärin und Grosskundin des Unternehmens. Damit schafft sie die Grundlage für eine nachhaltige Weiterentwicklung von LabPoint unter einer neuen Ankeraktionärin. LabPoint soll ihre Position in der Labordiagnostik weiter stärken und gezielt ausbauen.
Mehr erfahren